// App-Quantinova.ai

TPS633 : An open-label, single-arm, phase II study of pertuzumab with high-dose trastuzumab for treatment of central nervous system (CNS) progression post-radiotherapy in patients (pts) with HER2-positive metastatic breast cancer (MBC): PATRICIA.

Researchers

Presenter

  • Nancy U. Lin

Principal Investigators

  • Catherine Lai

  • Andrea Lacasia

  • Alisha Stein

  • Bongin Yoo

  • Anita Fung

  • Mark D. Pegram

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Genentech, Inc., South San Francisico, CA

  • Stanford University Cancer Institute, Stanford, CA

Locations

  • United States

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Congestive heart failure

  • Solid malignancies

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab emtansine

  • Pertuzumab

  • Lapatinib

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

Phase

  • II

Study Id's

  • NCT02536339

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved